51052-05-2

Basic information

• Product Name: Pyrazino[1,2-a]benzimidazol-1(2H)-one, 3,4-dihydro- (9CI)
• Synonyms: Pyrazino[1,2-a]benzimidazol-1(2H)-one, 3,4-dihydro- (9CI);3,4-DIHYDRO-PYRAZINO[1,2-A]BENZIMIDAZOL-1(2H)-ONE
• CAS NO: 51052-05-2
• Molecular Formula: C₁₀H₉N₃O
• Molecular Weight: 187.19796
• Product Categories: PIPERIDINE;BENZIMIDAZOLE
• Mol File: 51052-05-2.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.49±0.1 g/cm3(Predicted)
• PKA: 13.34±0.20(Predicted)
• CAS DataBase Reference: Pyrazino[1,2-a]benzimidazol-1(2H)-one, 3,4-dihydro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrazino[1,2-a]benzimidazol-1(2H)-one, 3,4-dihydro- (9CI)(51052-05-2)
• EPA Substance Registry System: Pyrazino[1,2-a]benzimidazol-1(2H)-one, 3,4-dihydro- (9CI)(51052-05-2)

Safety Data

• Hazardous Substances Data: 51052-05-2(Hazardous Substances Data)

Upstream product

• 2849-93-6 2-benzimidazolecarboxylic acid 

Relevant articles and documents

Fragment-Based Optimization of Dihydropyrazino-Benzimidazolones as Metabotropic Glutamate Receptor-2 Positive Allosteric Modulators against Migraine

Our previous scaffold-hopping attempts resulted in dihydropyrazino-benzimidazoles as metabotropic glutamate receptor-2 (mGluR2) positive allosteric modulators (PAMs) with suboptimal drug-like profiles. Here, we report an alternative fragment-based optimization strategy applied on the new dihydropyrazino-benzimidazolone scaffold. Analyzing published high-affinity mGluR2 PAMs, we used a pharmacophore-guided approach to identify suitable growing vectors and optimize the scaffold in these directions. This strategy resulted in a new fragment like lead (34) with improved druglike properties that were translated to sufficient pharmacokinetics and validated proof-of-concept studies in migraine. Gratifyingly, compound34showed reasonable activity in the partial infraorbital nerve ligation, a migraine disease model that might open this indication for mGluR2 PAMs.